CD274 and non-small cell lung carcinoma: IV期无驱动基因、非鳞癌NSCLC治疗− I级推荐:帕博利珠单抗单药[限PD-L1 TPS≥50%(1A类证据),PD-L1 TPS 1%-49%(2A类证据)];帕博利珠单抗联合培美曲塞和铂类(1A类证据)− II级推荐:卡瑞利珠单抗联合培美曲塞和铂类(1A类证据);紫杉醇+卡铂+贝伐珠单抗+阿替利珠单抗(1A类证据);白蛋白紫杉醇+卡铂+阿替利珠单抗(1A类证据)无驱动基因、IV期鳞癌的治疗− I级推荐:帕博利珠单抗单药[PD-L1 TPS≥50%(1A类证据),PD-L1 TPS 1%-49%(2A类证据)];帕博利珠单抗联合紫杉醇/白蛋白紫杉醇和铂类(1A类证据)